Diffuse Large B-Cell Lymphoma News

Conference Coverage

Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL

12/11/2023

Amber Denham ;

Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...

Glofitamab plus polatuzumab...

12/11/2023

Oncology

News

Tafasitamab Plus R-CHOP With or Without Lenalidomide Yields Encouraging Efficacy, Manageable Safety Among Patients With Untreated DLBCL

11/28/2023

Jordan Kadish ;

A combination of tafasitamab plus R-CHOP with or without the addition of lenalidomide demonstrated encouraging efficacy and manageable safety among patients with untreated diffuse large B-cell lymphoma, according to study results.

A combination of tafasitamab...

11/28/2023

Oncology

News

BTK Inhibitor Acalabrutinib Plus STAT3 Inhibitor Danvatirsen for R/R DLBCL

11/15/2023

Jordan Kadish ;

BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen therapy yielded safe and tolerable outcomes among patients with R/R DLBCL, but demonstrated limited efficacy outcomes, according to a phase 1 study.

BTK inhibitor acalabrutinib plus...

11/15/2023

Oncology

News

Comparing Chemotherapy Cycles Using Positron Emission Tomography-Adapted Therapy Among Patients With Non-Bulky, Low-Risk DLBCL

10/24/2023

Jordan Kadish ;

A 4-cycle regimen of chemotherapy showed comparable efficacy to a 6-cycle regimen for patients with low-risk, non-bulky DLBCL with interim positron emission tomography with computed tomography confirmed complete response, according to a phase...

A 4-cycle regimen of...

10/24/2023

Oncology

News

Mosunetuzumab Monotherapy Yields Notable Efficacy, Manageable Safety for R/R DLBCL, Including for Patients With Prior CAR T-Cell Therapy

09/26/2023

Jordan Kadish ;

Mosunetuzumab monotherapy demonstrated strong efficacy and a manageable safety profile among patients with relapsed/refractory diffuse large B-cell lymphoma, including those previously treated with CAR T-cell therapy.

Mosunetuzumab monotherapy...

09/26/2023

Oncology

News

Predictive Value of CIRS-Derived Comorbidity Index for Patients With R/R DLBCL Indicated for CAR T-Cell Therapy

08/30/2023

Jordan Kadish ;

A simplified CIRS-derived comorbidity index predicted outcomes among patients with R/R diffuse large B-cell lymphoma indicated for CAR T-cell therapy, according to a retrospective analysis.

A simplified CIRS-derived...

08/30/2023

Oncology

News

BET Inhibitor Trotabresib Demonstrated Antitumor Activity Among Patients With Heavily Pretreated R/R DLBCL

08/01/2023

Jordan Kadish ;

Oral BET inhibitor trotabresib showed antitumor activity profile among patients with heavily pretreated R/R diffuse large B-cell lymphoma or advanced solid tumors, demonstrating its potential value in combination with other anticancer agents.

Oral BET inhibitor trotabresib...

08/01/2023

Oncology

News

Upfront High-Dose Chemotherapy Followed by Auto-HSCT Improved Prognosis Among Patients With High-Intermediate/High-Risk Stage IV DLBCL

07/27/2023

Jordan Kadish ;

Upfront chemotherapy followed by autologous hematopoietic stem-cell transplantation yielded effective results among patients with intermediate/high-risk stage IV DLBCL not otherwise specified, according to a retrospective cohort study.

Upfront chemotherapy followed by...

07/27/2023

Oncology

News

Atezolizumab Plus R-CHOP Therapy Among Patients With Previously Untreated DLBCL

07/25/2023

Jordan Kadish ;

Atezolizumab plus R-CHOP demonstrated durable clinical efficacy among patients with previously untreated DLBCL, however the benefit compared with a regimen of R-CHOP alone is likely to be insignificant, according to a phase 1b/2 trial.

Atezolizumab plus R-CHOP...

07/25/2023

Oncology

News

Carfilzomib Plus R-ICE Regimen Well-Tolerated Among Patients With Relapsed/Refractory DLBCL

06/26/2023

Jordan Kadish ;

The addition of carfilzomib to the rituximab, ifosfamide, carboplatin, and etoposide treatment regimen was well-tolerated among patients with R/R DLBCL.

The addition of carfilzomib to...

06/26/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology